|
|
|
|
|
|
|
|
|
|
|
|
|
31.03.26 - 14:54
|
Valor Ranks No. 82 on 2026 Inc. Regionals: Southwest (PR Newswire)
|
|
|
In its fourth year on the list, Valor remains a regional growth leader, joining the 2026 cohort with an average 79% growth rate. FORT WORTH, Texas, March 31, 2026 /PRNewswire/ -- Valor, a Fort Worth-based tech-enabled professional services company that provides oil and gas asset......
|
|
|
31.03.26 - 11:06
|
Senior Researchers From NVIDIA, Samsung, NASA, University of Toronto Join AXL to Bring Global AI Expertise to Canadian Venture Creation (Business Wire)
|
|
|
TORONTO--(BUSINESS WIRE)--AXL, a Canadian venture studio transforming applied AI research into high-growth companies, has announced its inaugural cohort of Faculty Fellows, a group of nine distinguished researchers, all professors at the University of Toronto (U of T), whose work spans computer vision, machine learning, and beyond at some of the world's leading organizations.
Fellows include current and former senior scientists and engineers from NVIDIA, Samsung, Adobe, the National Aeronautics and Space Administration (NASA), and the University Health Network, who are joining AXL's growing scientific advisory bench to bring decades of industry and academic expertise to the ventures emerging from the studio. They are building on the significant industry depth among AXL's founding team, including those who have worked with Autodesk, Microsoft, Meta, Nortel, and Telus.
One of these fellows is Gennady Pekhimenko, who became a Senior Director of AI Software at NVIDIA after NVIDIA's 2025 acquisition of his...
|
|
|
30.03.26 - 22:48
|
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights (Business Wire)
|
|
|
Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia.
DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Completion Expected in 1H 2026.
ReMEDy2 Phase 2/3 AIS Trial of DM199 Approaching 70% of Required Interim Enrollment; Interim Analysis planned 2H 2026.
$60 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2H 2027.
Conference Call and Webcast on March 31 at 8:00 AM ET / 7:00 AM CT.
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS), today provided a business update and reported financial results for the year ended December 31, 2025. Management will host a conference call on Tuesday, March 31, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update a...
|
|
|
|
|
|
|
27.03.26 - 13:03
|
Adagio Medical Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
|
|
|
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the fourth quarter ended December 31, 2025.
Fourth Quarter and Recent Business Highlights:
Announced the peer-reviewed publication in Circulation: Arrythmia and Electrophysiology, highlighting results from the U.S. Early Feasibility Study evaluating ultralow temperature cardiac ablation (“ULTA”) for the treatment of scar-related ventricular tachycardia (“VT”), which demonstrated a favorable safety profile and no device- or procedure-related major adverse events in a real-world patient cohort of both ischemic and challenging non-ischemic patients
Announced the successful completion of 13 cases with the vCLAS™ System under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”). The procedures, which included patients ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
